All In Biotech

Drug Trial Radar · NCT01850524

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jul 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

705

Actual

Start

Apr 29, 2013

Primary completion

Dec 2, 2019

Study completion Jun 24, 2022

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
May 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.

Conditions

  • Multiple Myeloma

Interventions

  • IxazomibDrug

    IXAZOMIB capsules.

  • PlaceboDrug

    IXAZOMIB matching-placebo capsules.

  • DexamethasoneDrug

    Dexamethasone tablets.

  • LenalidomideDrug

    Lenalidomide capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 79 months

Locations

147 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Corona, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Fullerton, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Mission Hills, California

  • Site not named

    Oakland, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    San Jose, California

  • Site not named

    San Leandro, California

  • Site not named

    Santa Clara, California

  • Site not named

    South San Francisco, California

  • Site not named

    Vallejo, California

  • Site not named

    Denver, Colorado

  • Site not named

    Fort Collins, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    Plainville, Connecticut

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Iowa City, Iowa

  • Site not named

    Sioux City, Iowa

  • Site not named

    Louisville, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Towson, Maryland

  • Site not named

    Burlington, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.